{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T00:19:04Z","timestamp":1792887544057,"version":"4.5.0"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    X-linked hypophosphatemia is a rare genetic disease caused by pathogenic variants in the\u00a0\n                    <jats:italic>PHEX<\/jats:italic>\n                    (phosphate-regulating endopeptidase homolog X-linked) gene with X-linked dominant inheritance that causes metabolic bone disease and other severe complications. PHEX dysfunction results in increased production and secretion of the phosphaturic hormone fibroblast growth factor 23 (FGF23) from bone. The consequences of FGF23 excess are renal phosphate wasting and decreased calcitriol synthesis, leading to hypophosphatemia and subsequently rickets and osteomalacia. Children with XLH usually become symptomatic in the second year of life presenting with progressive disproportionate short stature, bone pain, frontal bossing, enlarged joints, bowed legs, and a waddling gait. Various other symptoms may develop later, including dental abscesses, peritonitis, hearing loss, pseudofractures, spinal stenosis, osteoarthritis, and enthesopathies, often leading to a diminished quality of life and ultimately disability. Here, we provide an overview of the current knowledge of the pathophysiology and treatment insights of this rare and challenging disease, including the targeting of FGF23 as a therapeutic approach that has significantly improved patient outcomes.\n                  <\/jats:p>","DOI":"10.1007\/s00223-025-01374-w","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T13:52:12Z","timestamp":1745848332000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The Diagnosis and Therapy of XLH"],"prefix":"10.1007","volume":"116","author":[{"given":"Ineke","family":"B\u00f6ckmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9601-7813","authenticated-orcid":false,"given":"Dieter","family":"Haffner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"issue":"3","key":"1374_CR1","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1530\/eje-08-0818","volume":"160","author":"SS Beck-Nielsen","year":"2009","unstructured":"Beck-Nielsen SS, Brock-Jacobsen B, Gram J, Brixen K, Jensen TK (2009) Incidence and prevalence of nutritional and hereditary rickets in southern Denmark. Eur J Endocrinol 160(3):491\u20137. https:\/\/doi.org\/10.1530\/eje-08-0818","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"1374_CR2","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1507\/endocrj.ej15-0275","volume":"62","author":"I Endo","year":"2015","unstructured":"Endo I, Fukumoto S, Ozono K, Namba N, Inoue D, Okazaki R et al (2015) Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment. Endocr J 62(9):811\u20136. https:\/\/doi.org\/10.1507\/endocrj.ej15-0275","journal-title":"Endocr J"},{"issue":"1","key":"1374_CR3","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13023-019-1014-8","volume":"14","author":"SS Beck-Nielsen","year":"2019","unstructured":"Beck-Nielsen SS, Mughal Z, Haffner D, Nilsson O, Levtchenko E, Ariceta G et al (2019) FGF23 and its role in X-linked hypophosphatemia-related morbidity. Orphanet J Rare Dis 14(1):58. https:\/\/doi.org\/10.1186\/s13023-019-1014-8","journal-title":"Orphanet J Rare Dis"},{"issue":"10455","key":"1374_CR4","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/s0140-6736(24)01305-9","volume":"404","author":"P Kamenick\u00fd","year":"2024","unstructured":"Kamenick\u00fd P, Briot K, Munns CF, Linglart A (2024) X-linked hypophosphataemia. Lancet 404(10455):887\u2013901. https:\/\/doi.org\/10.1016\/s0140-6736(24)01305-9","journal-title":"Lancet"},{"issue":"6","key":"1374_CR5","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41574-022-00662-x","volume":"18","author":"A Trombetti","year":"2022","unstructured":"Trombetti A, Al-Daghri N, Brandi ML, Cannata-And\u00eda JB, Cavalier E, Chandran M et al (2022) Interdisciplinary management of FGF23-related phosphate wasting syndromes: a Consensus Statement on the evaluation, diagnosis and care of patients with X-linked hypophosphataemia. Nat Rev Endocrinol 18(6):366\u201384. https:\/\/doi.org\/10.1038\/s41574-022-00662-x","journal-title":"Nat Rev Endocrinol"},{"issue":"7","key":"1374_CR6","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41581-019-0152-5","volume":"15","author":"D Haffner","year":"2019","unstructured":"Haffner D, Emma F, Eastwood DM, Duplan MB, Bacchetta J, Schnabel D et al (2019) Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol 15(7):435\u2013455. https:\/\/doi.org\/10.1038\/s41581-019-0152-5","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"1374_CR7","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1186\/s13023-023-02882-4","volume":"18","author":"G Ariceta","year":"2023","unstructured":"Ariceta G, Beck-Nielsen SS, Boot AM, Brandi ML, Briot K, de Lucas CC et al (2023) The International X-Linked Hypophosphatemia (XLH) Registry: first interim analysis of baseline demographic, genetic and clinical data. Orphanet J Rare Dis 18(1):304. https:\/\/doi.org\/10.1186\/s13023-023-02882-4","journal-title":"Orphanet J Rare Dis"},{"issue":"10","key":"1374_CR8","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1093\/jbmr\/zjae127","volume":"39","author":"AA Portale","year":"2024","unstructured":"Portale AA, Ward L, Dahir K, Florenzano P, Ing SW, Jan de Beur SM et al (2024) Nephrocalcinosis and kidney function in children and adults with X-linked hypophosphatemia: baseline results from a large longitudinal study. J Bone Miner Res 39(10):1493\u2013502. https:\/\/doi.org\/10.1093\/jbmr\/zjae127","journal-title":"J Bone Miner Res"},{"key":"1374_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-024-00926-x","author":"D Haffner","year":"2025","unstructured":"Haffner D, Emma F, Seefried L, H\u00f6gler W, Javaid KM, Bockenhauer D et al (2025) Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol. https:\/\/doi.org\/10.1038\/s41581-024-00926-x","journal-title":"Nat Rev Nephrol"},{"issue":"5","key":"1374_CR10","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.kint.2018.08.022","volume":"94","author":"F Emma","year":"2018","unstructured":"Emma F, Haffner D (2018) FGF23 blockade coming to clinical practice. Kidney Int 94(5):846\u2013848. https:\/\/doi.org\/10.1016\/j.kint.2018.08.022","journal-title":"Kidney Int"},{"issue":"4","key":"1374_CR11","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1172\/jci72829","volume":"124","author":"TO Carpenter","year":"2014","unstructured":"Carpenter TO, Imel EA, Ruppe MD, Weber TJ, Klausner MA, Wooddell MM et al (2014) Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. J Clin Invest 124(4):1587\u201397. https:\/\/doi.org\/10.1172\/jci72829","journal-title":"J Clin Invest"},{"issue":"11","key":"1374_CR12","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1359\/jbmr.090509","volume":"24","author":"Y Aono","year":"2009","unstructured":"Aono Y, Yamazaki Y, Yasutake J, Kawata T, Hasegawa H, Urakawa I et al (2009) Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets\/osteomalacia. J Bone Miner Res 24(11):1879\u20131888. https:\/\/doi.org\/10.1359\/jbmr.090509. (PubMed PMID: 19419316)","journal-title":"J Bone Miner Res"},{"issue":"2","key":"1374_CR13","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1359\/jbmr.2002.17.2.311","volume":"17","author":"DL Thompson","year":"2002","unstructured":"Thompson DL, Sabbagh Y, Tenenhouse HS, Roche PC, Drezner MK, Salisbury JL et al (2002) Ontogeny of Phex\/PHEX protein expression in mouse embryo and subcellular localization in osteoblasts. J Bone Miner Res 17(2):311\u2013320. https:\/\/doi.org\/10.1359\/jbmr.2002.17.2.311. (PubMed PMID: 11811562)","journal-title":"J Bone Miner Res"},{"issue":"2","key":"1374_CR14","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/humu.24296","volume":"43","author":"S Sarafrazi","year":"2022","unstructured":"Sarafrazi S, Daugherty SC, Miller N, Boada P, Carpenter TO, Chunn L et al (2022) Novel PHEX gene locus-specific database: comprehensive characterization of vast number of variants associated with X-linked hypophosphatemia (XLH). Hum Mutat 43(2):143\u201357. https:\/\/doi.org\/10.1002\/humu.24296","journal-title":"Hum Mutat"},{"issue":"5658","key":"1374_CR15","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1126\/science.1092727","volume":"303","author":"I Okamoto","year":"2004","unstructured":"Okamoto I, Otte AP, Allis CD, Reinberg D, Heard E (2004) Epigenetic dynamics of imprinted X inactivation during early mouse development. Science 303(5658):644\u20139. https:\/\/doi.org\/10.1126\/science.1092727","journal-title":"Science"},{"issue":"4","key":"1374_CR16","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1093\/ejendo\/lvad144","volume":"189","author":"E Boros","year":"2023","unstructured":"Boros E, Ertl DA, Berkenou J, Audrain C, Lecoq AL, Kamenicky P et al (2023) Adult height improved over decades in patients with X-linked hypophosphatemia: a cohort study. Eur J Endocrinol 189(4):469\u2013475. https:\/\/doi.org\/10.1093\/ejendo\/lvad144. (PubMed PMID: 37831782)","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"1374_CR17","doi-asserted-by":"publisher","first-page":"4075","DOI":"10.1210\/jcem.81.11.8923863","volume":"81","author":"MP Whyte","year":"1996","unstructured":"Whyte MP, Schranck FW, Armamento-Villareal R (1996) X-linked hypophosphatemia: a search for gender, race, anticipation, or parent of origin effects on disease expression in children. J Clin Endocrinol Metab 81(11):4075\u20134080. https:\/\/doi.org\/10.1210\/jcem.81.11.8923863. (PubMed PMID: 8923863)","journal-title":"J Clin Endocrinol Metab"},{"key":"1374_CR18","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.bone.2019.01.021","volume":"121","author":"C Zhang","year":"2019","unstructured":"Zhang C, Zhao Z, Sun Y, Xu L, JiaJue R, Cui L et al (2019) Clinical and genetic analysis in a large Chinese cohort of patients with X-linked hypophosphatemia. Bone. 121:212\u201320. https:\/\/doi.org\/10.1016\/j.bone.2019.01.021","journal-title":"Bone."},{"key":"1374_CR19","doi-asserted-by":"publisher","unstructured":"Gattineni J, Alphonse P, Zhang Q, Mathews N, Bates CM, Baum M. Regulation of renal phosphate transport by FGF23 is mediated by FGFR1 and FGFR4. Am J Physiol Renal Physiol. 2014;306(3):F351\u20138. Epub 20131120. https:\/\/doi.org\/10.1152\/ajprenal.00232.2013. PubMed PMID: 24259513; PubMed Central PMCID: PMCPMC3920047.","DOI":"10.1152\/ajprenal.00232.2013"},{"issue":"2","key":"1374_CR20","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.bone.2004.04.002","volume":"35","author":"A Benet-Pag\u00e8s","year":"2004","unstructured":"Benet-Pag\u00e8s A, Lorenz-Depiereux B, Zischka H, White KE, Econs MJ, Strom TM (2004) FGF23 is processed by proprotein convertases but not by PHEX. Bone 35(2):455\u2013462. https:\/\/doi.org\/10.1016\/j.bone.2004.04.002. (PubMed PMID: 15268897)","journal-title":"Bone"},{"issue":"3","key":"1374_CR21","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1002\/jbmr.1766","volume":"28","author":"NM Barros","year":"2013","unstructured":"Barros NM, Hoac B, Neves RL, Addison WN, Assis DM, Murshed M et al (2013) Proteolytic processing of osteopontin by PHEX and accumulation of osteopontin fragments in Hyp mouse bone, the murine model of X-linked hypophosphatemia. J Bone Miner Res 28(3):688\u2013699. https:\/\/doi.org\/10.1002\/jbmr.1766. (PubMed PMID: 22991293)","journal-title":"J Bone Miner Res"},{"issue":"4","key":"1374_CR22","doi-asserted-by":"publisher","first-page":"e1002427","DOI":"10.1371\/journal.pbio.1002427","volume":"14","author":"SK Murali","year":"2016","unstructured":"Murali SK, Andrukhova O, Clinkenbeard EL, White KE, Erben RG (2016) Excessive osteocytic Fgf23 secretion contributes to pyrophosphate accumulation and mineralization defect in Hyp mice. PLoS Biol. 14(4):e1002427. https:\/\/doi.org\/10.1371\/journal.pbio.1002427","journal-title":"PLoS Biol."},{"issue":"4","key":"1374_CR23","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1074\/jbc.M112.410043","volume":"288","author":"M Kawai","year":"2013","unstructured":"Kawai M, Kinoshita S, Kimoto A, Hasegawa Y, Miyagawa K, Yamazaki M et al (2013) FGF23 suppresses chondrocyte proliferation in the presence of soluble \u03b1-Klotho both in vitro and in vivo. J Biol Chem. 288(4):2414\u201327. https:\/\/doi.org\/10.1074\/jbc.M112.410043","journal-title":"J Biol Chem."},{"issue":"7","key":"1374_CR24","doi-asserted-by":"publisher","first-page":"8349","DOI":"10.1096\/fj.201802007R","volume":"33","author":"R Fuente","year":"2019","unstructured":"Fuente R, Gil-Pe\u00f1a H, Claramunt-Taberner D, Hern\u00e1ndez-Fr\u00edas O, Fern\u00e1ndez-Iglesias \u00c1, Alonso-Dur\u00e1n L et al (2019) MAPK inhibition and growth hormone: a promising therapy in XLH. Faseb J. 33(7):8349\u201362. https:\/\/doi.org\/10.1096\/fj.201802007R","journal-title":"Faseb J."},{"issue":"sup1","key":"1374_CR25","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1080\/03008207.2017.1417989","volume":"59","author":"BR Coyac","year":"2018","unstructured":"Coyac BR, Falgayrac G, Penel G, Schmitt A, Schinke T, Linglart A et al (2018) Impaired mineral quality in dentin in X-linked hypophosphatemia. Connect Tissue Res 59(sup1):91\u201396. https:\/\/doi.org\/10.1080\/03008207.2017.1417989. (PubMed PMID: 29745817)","journal-title":"Connect Tissue Res"},{"issue":"9","key":"1374_CR26","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1007\/s00467-021-05328-w","volume":"37","author":"D Haffner","year":"2022","unstructured":"Haffner D, Leifheit-Nestler M, Grund A, Schnabel D (2022) Rickets guidance: part I-diagnostic workup. Pediatr Nephrol. 37(9):2013\u201336. https:\/\/doi.org\/10.1007\/s00467-021-05328-w","journal-title":"Pediatr Nephrol."},{"issue":"1","key":"1374_CR27","first-page":"22","volume":"22","author":"WB Greene","year":"1996","unstructured":"Greene WB (1996) Genu varum and genu valgum in children: differential diagnosis and guidelines for evaluation. Compr Ther 22(1):22\u201329 (PubMed PMID: 8654021)","journal-title":"Compr Ther"},{"issue":"3","key":"1374_CR28","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1002\/jbmr.3614","volume":"34","author":"A Rothenbuhler","year":"2019","unstructured":"Rothenbuhler A, Fadel N, Debza Y, Bacchetta J, Diallo MT, Adamsbaum C et al (2019) High incidence of cranial synostosis and chiari i malformation in children with X-linked hypophosphatemic rickets (XLHR). J Bone Miner Res. 34(3):490\u20136. https:\/\/doi.org\/10.1002\/jbmr.3614","journal-title":"J Bone Miner Res."},{"issue":"2","key":"1374_CR29","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s00467-010-1705-9","volume":"26","author":"M Zivi\u010dnjak","year":"2011","unstructured":"Zivi\u010dnjak M, Schnabel D, Billing H, Staude H, Filler G, Querfeld U et al (2011) Age-related stature and linear body segments in children with X-linked hypophosphatemic rickets. Pediatr Nephrol. 26(2):223\u201331. https:\/\/doi.org\/10.1007\/s00467-010-1705-9","journal-title":"Pediatr Nephrol."},{"issue":"1","key":"1374_CR30","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s00198-020-05548-0","volume":"32","author":"L Seefried","year":"2021","unstructured":"Seefried L, Smyth M, Keen R, Harvengt P (2021) Burden of disease associated with X-linked hypophosphataemia in adults: a systematic literature review. Osteoporos Int. 32(1):7\u201322. https:\/\/doi.org\/10.1007\/s00198-020-05548-0","journal-title":"Osteoporos Int."},{"key":"1374_CR31","doi-asserted-by":"publisher","DOI":"10.1093\/jbmrpl\/ziae118","author":"N Namba","year":"2024","unstructured":"Namba N, Ito N, Michigami T, Kang HG, Kubota T, Miyazaki O et al (2024) Impact of X-linked hypophosphatemic rickets\/osteomalacia on health and quality of life: baseline data from the SUNFLOWER longitudinal, observational cohort study. JBMR Plus. https:\/\/doi.org\/10.1093\/jbmrpl\/ziae118","journal-title":"JBMR Plus"},{"key":"1374_CR32","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.bone.2019.02.010","volume":"122","author":"TD Thacher","year":"2019","unstructured":"Thacher TD, Pettifor JM, Tebben PJ, Creo AL, Skrinar A, Mao M et al (2019) Rickets severity predicts clinical outcomes in children with X-linked hypophosphatemia: Utility of the radiographic Rickets Severity Score. Bone 122:76\u201381. https:\/\/doi.org\/10.1016\/j.bone.2019.02.010","journal-title":"Bone"},{"issue":"6","key":"1374_CR33","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1080\/10408363.2017.1379945","volume":"54","author":"K Adeli","year":"2017","unstructured":"Adeli K, Higgins V, Trajcevski K, White-Al Habeeb N (2017) The Canadian laboratory initiative on pediatric reference intervals: A CALIPER white paper. Crit Rev Clin Lab Sci. 54(6):358\u2013413. https:\/\/doi.org\/10.1080\/10408363.2017.1379945","journal-title":"Crit Rev Clin Lab Sci."},{"issue":"3","key":"1374_CR34","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1210\/clinem\/dgad597","volume":"109","author":"V Pott","year":"2024","unstructured":"Pott V, Tietze H, Kanzelmeyer N, von der Born J, Baumann U, Mindermann C et al (2024) LMS-based pediatric reference values for parameters of phosphate homeostasis in the HARP cohort. J Clin Endocrinol Metab 109(3):668\u2013679. https:\/\/doi.org\/10.1210\/clinem\/dgad597. (PubMed PMID: 37850343)","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1374_CR35","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/bf00862587","volume":"2","author":"J Brodehl","year":"1988","unstructured":"Brodehl J, Krause A, Hoyer PF (1988) Assessment of maximal tubular phosphate reabsorption: comparison of direct measurement with the nomogram of Bijvoet. Pediatr Nephrol 2(2):183\u2013189. https:\/\/doi.org\/10.1007\/bf00862587. (PubMed PMID: 3153009)","journal-title":"Pediatr Nephrol"},{"issue":"5","key":"1374_CR36","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/bf00858154","volume":"8","author":"J Brodehl","year":"1994","unstructured":"Brodehl J (1994) Assessment and interpretation of the tubular threshold for phosphate in infants and children. Pediatr Nephrol 8(5):645. https:\/\/doi.org\/10.1007\/bf00858154. (PubMed PMID: 7819020)","journal-title":"Pediatr Nephrol"},{"issue":"4","key":"1374_CR37","first-page":"163","volume":"17","author":"J Brodehl","year":"1982","unstructured":"Brodehl J, Gellissen K, Weber HP (1982) Postnatal development of tubular phosphate reabsorption. Clin Nephrol 17(4):163\u2013171 (PubMed PMID: 7075034)","journal-title":"Clin Nephrol"},{"issue":"2","key":"1374_CR38","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1007\/bf00865491","volume":"8","author":"U Alon","year":"1994","unstructured":"Alon U, Hellerstein S (1994) Assessment and interpretation of the tubular threshold for phosphate in infants and children. Pediatr Nephrol 8(2):250\u2013251. https:\/\/doi.org\/10.1007\/bf00865491. (PubMed PMID: 8018507)","journal-title":"Pediatr Nephrol"},{"issue":"7929","key":"1374_CR39","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/s0140-6736(75)92736-1","volume":"2","author":"RJ Walton","year":"1975","unstructured":"Walton RJ, Bijvoet OL (1975) Nomogram for derivation of renal threshold phosphate concentration. Lancet 2(7929):309\u2013310. https:\/\/doi.org\/10.1016\/s0140-6736(75)92736-1. (PubMed PMID: 50513)","journal-title":"Lancet"},{"issue":"8","key":"1374_CR40","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1001\/archinte.1991.00400080083015","volume":"151","author":"C G\u00f6k\u00e7e","year":"1991","unstructured":"G\u00f6k\u00e7e C, G\u00f6k\u00e7e O, Baydin\u00e7 C, Ilhan N, Ala\u015fehirli E, Ozk\u00fc\u00e7\u00fck F et al (1991) Use of random urine samples to estimate total urinary calcium and phosphate excretion. Arch Intern Med 151(8):1587\u20131588. https:\/\/doi.org\/10.1001\/archinte.1991.00400080083015. (PubMed PMID: 1872663)","journal-title":"Arch Intern Med"},{"issue":"11","key":"1374_CR41","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1093\/ndt\/gfab331","volume":"37","author":"L Derain Dubourg","year":"2022","unstructured":"Derain Dubourg L, Aurelle M, Chardon L, Flammier S, Lemoine S, Bacchetta J (2022) Tubular phosphate handling: references from child to adulthood in the era of standardized serum creatinine. Nephrol Dial Transplant 37(11):2150\u20132156. https:\/\/doi.org\/10.1093\/ndt\/gfab331. (PubMed PMID: 34850142)","journal-title":"Nephrol Dial Transplant"},{"key":"1374_CR42","unstructured":"ESPN. TmP\/GFR calculator 2025. Available from: https:\/\/www.espn-online.org\/tmp-gfr-calculator\/."},{"issue":"11","key":"1374_CR43","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1002\/jbmr.4702","volume":"37","author":"IR Hartley","year":"2022","unstructured":"Hartley IR, Gafni RI, Roszko KL, Brown SM, de Castro LF, Saikali A et al (2022) Determination of FGF23 levels for the diagnosis of FGF23-mediated hypophosphatemia. J Bone Miner Res 37(11):2174\u201385. https:\/\/doi.org\/10.1002\/jbmr.4702","journal-title":"J Bone Miner Res"},{"key":"1374_CR44","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.bonr.2017.09.002","volume":"7","author":"P Florenzano","year":"2017","unstructured":"Florenzano P, Gafni RI, Collins MT (2017) Tumor-induced osteomalacia. Bone Rep 7:90\u20137. https:\/\/doi.org\/10.1016\/j.bonr.2017.09.002","journal-title":"Bone Rep"},{"issue":"1","key":"1374_CR45","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s12020-024-04097-4","volume":"88","author":"R Chimenz","year":"2025","unstructured":"Chimenz R, Columbu C, Pugliese F, Arena A, Bonifazi Meffe L, Carbone V et al (2025) Hypophosphatemic rickets in an Italian multicentric cohort of 24 subjects: a clinical and molecular characterisation. Endocrine 88(1):285\u201394. https:\/\/doi.org\/10.1007\/s12020-024-04097-4","journal-title":"Endocrine"},{"issue":"21","key":"1374_CR46","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","volume":"378","author":"TO Carpenter","year":"2018","unstructured":"Carpenter TO, Whyte MP, Imel EA, Boot AM, H\u00f6gler W, Linglart A et al (2018) Burosumab therapy in children with X-linked hypophosphatemia. N Engl J Med 378(21):1987\u20131998. https:\/\/doi.org\/10.1056\/NEJMoa1714641. (PubMed PMID: 29791829)","journal-title":"N Engl J Med"},{"issue":"8","key":"1374_CR47","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1002\/jbmr.3475","volume":"33","author":"KL Insogna","year":"2018","unstructured":"Insogna KL, Briot K, Imel EA, Kamenick\u00fd P, Ruppe MD, Portale AA et al (2018) A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis. J Bone Miner Res 33(8):1383\u201393. https:\/\/doi.org\/10.1002\/jbmr.3475","journal-title":"J Bone Miner Res"},{"issue":"2","key":"1374_CR48","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/cen.14832","volume":"99","author":"SL Ashrafzadeh-Kian","year":"2023","unstructured":"Ashrafzadeh-Kian SL, Ito N, Srivastava T, Garg U, Kato H, Algeciras-Schimnich A et al (2023) The effect of burosumab on intact and C-terminal FGF23 measurements. Clin Endocrinol (Oxf) 99(2):152\u20137. https:\/\/doi.org\/10.1111\/cen.14832","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"11","key":"1374_CR49","doi-asserted-by":"publisher","first-page":"e267","DOI":"10.1515\/cclm-2020-0460","volume":"58","author":"ML Piketty","year":"2020","unstructured":"Piketty ML, Brabant S, Souberbielle JC, Maruani G, Audrain C, Rothenbuhler A et al (2020) FGF23 measurement in burosumab-treated patients: an emerging treatment may induce a new analytical interference. Clin Chem Lab Med 58(11):e267\u2013e269. https:\/\/doi.org\/10.1515\/cclm-2020-0460. (PubMed PMID: 32653872)","journal-title":"Clin Chem Lab Med"},{"issue":"10189","key":"1374_CR50","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1016\/s0140-6736(19)30654-3","volume":"393","author":"EA Imel","year":"2019","unstructured":"Imel EA, Glorieux FH, Whyte MP, Munns CF, Ward LM, Nilsson O et al (2019) Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. Lancet 393(10189):2416\u201327. https:\/\/doi.org\/10.1016\/s0140-6736(19)30654-3","journal-title":"Lancet"},{"key":"1374_CR51","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-024-06427-0","author":"M Klein","year":"2024","unstructured":"Klein M, Obermaier M, Mutze H, Wilden SM, Rehberg M, Schlingmann KP et al (2024) Health-related quality of life of children with X-linked hypophosphatemia in Germany. Pediatr Nephrol. https:\/\/doi.org\/10.1007\/s00467-024-06427-0","journal-title":"Pediatr Nephrol."},{"issue":"3","key":"1374_CR52","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1210\/clinem\/dgab729","volume":"107","author":"A Linglart","year":"2022","unstructured":"Linglart A, Imel EA, Whyte MP, Portale AA, H\u00f6gler W, Boot AM et al (2022) Sustained efficacy and safety of burosumab, a monoclonal antibody to FGF23, in children with X-linked hypophosphatemia. J Clin Endocrinol Metab 107(3):813\u2013824. https:\/\/doi.org\/10.1210\/clinem\/dgab729","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"1374_CR53","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1002\/jbmr.3843","volume":"34","author":"KL Insogna","year":"2019","unstructured":"Insogna KL, Rauch F, Kamenick\u00fd P, Ito N, Kubota T, Nakamura A et al (2019) Burosumab improved histomorphometric measures of osteomalacia in adults with X-linked hypophosphatemia: a phase 3, single-arm. International Trial. J Bone Miner Res 34(12):2183\u201391. https:\/\/doi.org\/10.1002\/jbmr.3843","journal-title":"International Trial. J Bone Miner Res"},{"key":"1374_CR54","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002676","author":"P Kamenicky","year":"2023","unstructured":"Kamenicky P, Briot K, Brandi ML, Cohen-Solal M, Crowley RK, Keen R et al (2023) Benefit of burosumab in adults with X-linked hypophosphataemia (XLH) is maintained with long-term treatment. RMD Open. https:\/\/doi.org\/10.1136\/rmdopen-2022-002676","journal-title":"RMD Open"},{"key":"1374_CR55","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001714","author":"K Briot","year":"2021","unstructured":"Briot K, Portale AA, Brandi ML, Carpenter TO, Cheong HI, Cohen-Solal M et al (2021) Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension. RMD Open. https:\/\/doi.org\/10.1136\/rmdopen-2021-001714","journal-title":"RMD Open"},{"issue":"4","key":"1374_CR56","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00223-022-01006-7","volume":"111","author":"ML Brandi","year":"2022","unstructured":"Brandi ML, Jan de Beur S, Briot K, Carpenter T, Cheong HI, Cohen-Solal M et al (2022) Efficacy of burosumab in adults with X-linked Hypophosphatemia (XLH): a post hoc subgroup analysis of a randomized double-blind placebo-controlled phase 3 study. Calcif Tissue Int 111(4):409\u201318. https:\/\/doi.org\/10.1007\/s00223-022-01006-7","journal-title":"Calcif Tissue Int"},{"issue":"6","key":"1374_CR57","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1210\/clinem\/dgac732","volume":"108","author":"H Kato","year":"2023","unstructured":"Kato H, Okawa R, Ogasawara T, Hoshino Y, Hidaka N, Koga M et al (2023) Effect of conventional treatment on dental complications and ectopic ossifications among 30 adults with XLH. J Clin Endocrinol Metab 108(6):1405\u20131414. https:\/\/doi.org\/10.1210\/clinem\/dgac732. (PubMed PMID: 36524341)","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"1374_CR58","doi-asserted-by":"publisher","first-page":"2990","DOI":"10.1210\/clinem\/dgad230","volume":"108","author":"EA Imel","year":"2023","unstructured":"Imel EA, Glorieux FH, Whyte MP, Portale AA, Munns CF, Nilsson O et al (2023) Burosumab vs phosphate\/active vitamin D in pediatric X-linked hypophosphatemia: a subgroup analysis by dose level. J Clin Endocrinol Metab 108(11):2990\u20132998. https:\/\/doi.org\/10.1210\/clinem\/dgad230","journal-title":"J Clin Endocrinol Metab"},{"key":"1374_CR59","doi-asserted-by":"publisher","first-page":"947814","DOI":"10.3389\/fendo.2022.947814","volume":"13","author":"R Brener","year":"2022","unstructured":"Brener R, Zeitlin L, Lebenthal Y, Brener A (2022) Dental health of pediatric patients with X-linked hypophosphatemia (XLH) after three years of burosumab therapy. Front Endocrinol (Lausanne) 13:947814. https:\/\/doi.org\/10.3389\/fendo.2022.947814","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1374_CR60","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae398","author":"A Herv\u00e9","year":"2024","unstructured":"Herv\u00e9 A, Gadion M, Herrou J, Izart M, Linglart A, Cohen-Solal M et al (2024) Improved oral health in adults with X-linked hypophosphatemia treated with burosumab. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgae398","journal-title":"J Clin Endocrinol Metab."},{"key":"1374_CR61","unstructured":"Agency EM. Crysvita. 2018 Annex I - summary of product characteristics. In: Kirin K, editor"},{"issue":"10","key":"1374_CR62","doi-asserted-by":"publisher","first-page":"e998","DOI":"10.1210\/clinem\/dgad223","volume":"108","author":"A Ewert","year":"2023","unstructured":"Ewert A, Rehberg M, Schlingmann KP, Hiort O, John-Kroegel U, Metzing O et al (2023) Effects of burosumab treatment on mineral metabolism in children and adolescents with X-linked hypophosphatemia. J Clin Endocrinol Metab 108(10):e998\u2013e1006. https:\/\/doi.org\/10.1210\/clinem\/dgad223. (PubMed PMID: 37097907)","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1374_CR63","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1136\/archdischild-2022-324962","volume":"108","author":"EYX Walker","year":"2023","unstructured":"Walker EYX, Lindsay TAJ, Allgrove J, Marlais M, Bockenhauer D, Hayes W (2023) Burosumab in management of X-linked hypophosphataemia: a retrospective cohort study of growth and serum phosphate levels. Arch Dis Child 108(5):379\u201384. https:\/\/doi.org\/10.1136\/archdischild-2022-324962","journal-title":"Arch Dis Child"},{"issue":"Suppl 1","key":"1374_CR64","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1590\/s0036-36342009000700004","volume":"51","author":"JP Bonjour","year":"2009","unstructured":"Bonjour JP, Chevalley T, Ferrari S, Rizzoli R (2009) The importance and relevance of peak bone mass in the prevalence of osteoporosis. Salud Publica Mex 51(Suppl 1):S5-17. https:\/\/doi.org\/10.1590\/s0036-36342009000700004. (PubMed PMID: 19287894)","journal-title":"Salud Publica Mex"},{"issue":"7","key":"1374_CR65","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1089\/bfm.2020.0068","volume":"15","author":"J Saito","year":"2020","unstructured":"Saito J, Yakuwa N, Ishizuka T, Goto M, Yamatani A, Murashima A (2020) Belimumab concentrations in maternal serum and breast milk during breastfeeding and the safety assessment of the infant: a case study. Breastfeed Med 15(7):475\u20137. https:\/\/doi.org\/10.1089\/bfm.2020.0068","journal-title":"Breastfeed Med"},{"issue":"7","key":"1374_CR66","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1002\/jbmr.3992","volume":"35","author":"AL Lecoq","year":"2020","unstructured":"Lecoq AL, Chaumet-Riffaud P, Blanchard A, Dupeux M, Rothenbuhler A, Lambert B et al (2020) Hyperparathyroidism in patients with X-linked hypophosphatemia. J Bone Miner Res 35(7):1263\u201373. https:\/\/doi.org\/10.1002\/jbmr.3992","journal-title":"J Bone Miner Res"},{"issue":"3","key":"1374_CR67","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1177\/000992289203100311","volume":"31","author":"U Alon","year":"1992","unstructured":"Alon U, Lovell HB, Donaldson DL (1992) Nephrocalcinosis, hyperparathyroidism, and renal failure in familial hypophosphatemic rickets. Clin Pediatr (Phila) 31(3):180\u2013183. https:\/\/doi.org\/10.1177\/000992289203100311. (PubMed PMID: 1547591)","journal-title":"Clin Pediatr (Phila)"},{"issue":"2","key":"1374_CR68","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1046\/j.1365-2265.2003.01685.x","volume":"58","author":"O M\u00e4kitie","year":"2003","unstructured":"M\u00e4kitie O, Kooh SW, Sochett E (2003) Prolonged high-dose phosphate treatment: a risk factor for tertiary hyperparathyroidism in X-linked hypophosphatemic rickets. Clin Endocrinol (Oxf) 58(2):163\u2013168. https:\/\/doi.org\/10.1046\/j.1365-2265.2003.01685.x. (PubMed PMID: 12580931)","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"9","key":"1374_CR69","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.1210\/jc.2014-2017","volume":"99","author":"TO Carpenter","year":"2014","unstructured":"Carpenter TO, Olear EA, Zhang JH, Ellis BK, Simpson CA, Cheng D et al (2014) Effect of paricalcitol on circulating parathyroid hormone in X-linked hypophosphatemia: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 99(9):3103\u201311. https:\/\/doi.org\/10.1210\/jc.2014-2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1374_CR70","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/s0022-3476(05)82149-3","volume":"118","author":"A Bettinelli","year":"1991","unstructured":"Bettinelli A, Bianchi ML, Mazzucchi E, Gandolini G, Appiani AC (1991) Acute effects of calcitriol and phosphate salts on mineral metabolism in children with hypophosphatemic rickets. J Pediatr 118(3):372\u2013376. https:\/\/doi.org\/10.1016\/s0022-3476(05)82149-3. (PubMed PMID: 1847972)","journal-title":"J Pediatr"},{"issue":"7","key":"1374_CR71","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s004670050669","volume":"13","author":"TD Blydt-Hansen","year":"1999","unstructured":"Blydt-Hansen TD, Tenenhouse HS, Goodyer P (1999) PHEX expression in parathyroid gland and parathyroid hormone dysregulation in X-linked hypophosphatemia. Pediatr Nephrol 13(7):607\u2013611. https:\/\/doi.org\/10.1007\/s004670050669. (PubMed PMID: 10460513)","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"1374_CR72","doi-asserted-by":"publisher","first-page":"274","DOI":"10.14310\/horm.2002.1277","volume":"9","author":"MP Yavropoulou","year":"2010","unstructured":"Yavropoulou MP, Kotsa K, Gotzamani Psarrakou A, Papazisi A, Tranga T, Ventis S et al (2010) Cinacalcet in hyperparathyroidism secondary to X-linked hypophosphatemic rickets: case report and brief literature review. Hormones (Athens) 9(3):274\u20138. https:\/\/doi.org\/10.14310\/horm.2002.1277","journal-title":"Hormones (Athens)"},{"issue":"1","key":"1374_CR73","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1210\/endo-118-1-441","volume":"118","author":"LK Vaughn","year":"1986","unstructured":"Vaughn LK, Meyer RA Jr, Meyer MH (1986) Increased metabolic rate in X-linked hypophosphatemic mice. Endocrinology 118(1):441\u2013445. https:\/\/doi.org\/10.1210\/endo-118-1-441. (PubMed PMID: 3940855)","journal-title":"Endocrinology"},{"issue":"6","key":"1374_CR74","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.cmet.2012.11.001","volume":"16","author":"B Angelin","year":"2012","unstructured":"Angelin B, Larsson TE, Rudling M (2012) Circulating fibroblast growth factors as metabolic regulators\u2013a critical appraisal. Cell Metab 16(6):693\u2013705. https:\/\/doi.org\/10.1016\/j.cmet.2012.11.001. (PubMed PMID: 23217254)","journal-title":"Cell Metab"},{"issue":"2","key":"1374_CR75","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1210\/jc.2015-2175","volume":"101","author":"CF Munns","year":"2016","unstructured":"Munns CF, Shaw N, Kiely M, Specker BL, Thacher TD, Ozono K et al (2016) Global consensus recommendations on prevention and management of nutritional rickets. J Clin Endocrinol Metab. 101(2):394\u2013415. https:\/\/doi.org\/10.1210\/jc.2015-2175","journal-title":"J Clin Endocrinol Metab."},{"key":"1374_CR76","doi-asserted-by":"publisher","DOI":"10.2903\/j.efsa.2015.4101","author":"EFSA Panel on Dietetic Products NaA","year":"2015","unstructured":"EFSA Panel on Dietetic Products NaA (2015) Scientific opinion on dietary reference values for calcium. EFSA J. https:\/\/doi.org\/10.2903\/j.efsa.2015.4101","journal-title":"EFSA J"},{"key":"1374_CR77","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.bone.2019.06.025","volume":"127","author":"S DeLacey","year":"2019","unstructured":"DeLacey S, Liu Z, Broyles A, El-Azab SA, Guandique CF, James BC et al (2019) Hyperparathyroidism and parathyroidectomy in X-linked hypophosphatemia patients. Bone 127:386\u201392. https:\/\/doi.org\/10.1016\/j.bone.2019.06.025","journal-title":"Bone"},{"issue":"3","key":"1374_CR78","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00467-017-3820-3","volume":"33","author":"N Meyerhoff","year":"2018","unstructured":"Meyerhoff N, Haffner D, Staude H, W\u00fchl E, Marx M, Beetz R et al (2018) Effects of growth hormone treatment on adult height in severely short children with X-linked hypophosphatemic rickets. Pediatr Nephrol 33(3):447\u201356. https:\/\/doi.org\/10.1007\/s00467-017-3820-3","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"1374_CR79","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1186\/s13023-022-02590-5","volume":"17","author":"J Andr\u00e9","year":"2022","unstructured":"Andr\u00e9 J, Zhukouskaya VV, Lambert AS, Salles JP, Mignot B, Bardet C et al (2022) Growth hormone treatment improves final height in children with X-linked hypophosphatemia. Orphanet J Rare Dis 17(1):444. https:\/\/doi.org\/10.1186\/s13023-022-02590-5","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"1374_CR80","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1186\/s13023-022-02562-9","volume":"17","author":"DA Ertl","year":"2022","unstructured":"Ertl DA, Le Lorier J, Gleiss A, Trabado S, Bensignor C, Audrain C et al (2022) Growth pattern in children with X-linked hypophosphatemia treated with burosumab and growth hormone. Orphanet J Rare Dis 17(1):412. https:\/\/doi.org\/10.1186\/s13023-022-02562-9","journal-title":"Orphanet J Rare Dis"},{"issue":"7","key":"1374_CR81","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.arcped.2021.09.003","volume":"28","author":"FD Rocco","year":"2021","unstructured":"Rocco FD, Rothenbuhler A, Adamsbaum C, Bacchetta J, Pejin Z, Finidori G et al (2021) Orthopedic and neurosurgical care of X-linked hypophosphatemia. Arch Pediatr 28(7):599\u2013605. https:\/\/doi.org\/10.1016\/j.arcped.2021.09.003","journal-title":"Arch Pediatr"},{"issue":"8","key":"1374_CR82","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1530\/ec-17-0154.PubMedPMID:28954742;PubMedCentralPMCID:PMCPMC5633063","volume":"6","author":"A Gizard","year":"2017","unstructured":"Gizard A, Rothenbuhler A, Pejin Z, Finidori G, Glorion C, de Billy B et al (2017) Outcomes of orthopedic surgery in a cohort of 49 patients with X-linked hypophosphatemic rickets (XLHR). Endocr Connect 6(8):566\u2013573. https:\/\/doi.org\/10.1530\/ec-17-0154.PubMedPMID:28954742;PubMedCentralPMCID:PMCPMC5633063","journal-title":"Endocr Connect"},{"issue":"3","key":"1374_CR83","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1530\/eje-15-0661","volume":"174","author":"H Che","year":"2016","unstructured":"Che H, Roux C, Etcheto A, Rothenbuhler A, Kamenicky P, Linglart A et al (2016) Impaired quality of life in adults with X-linked hypophosphatemia and skeletal symptoms. Eur J Endocrinol 174(3):325\u2013333. https:\/\/doi.org\/10.1530\/eje-15-0661. (PubMed PMID: 26783348)","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"1374_CR84","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1210\/js.2018-00365","volume":"3","author":"A Skrinar","year":"2019","unstructured":"Skrinar A, Dvorak-Ewell M, Evins A, Macica C, Linglart A, Imel EA et al (2019) The lifelong impact of X-linked hypophosphatemia: results from a burden of disease survey. J Endocr Soc 3(7):1321\u201334. https:\/\/doi.org\/10.1210\/js.2018-00365","journal-title":"J Endocr Soc"},{"issue":"3","key":"1374_CR85","doi-asserted-by":"publisher","first-page":"e1249","DOI":"10.1210\/clinem\/dgab739.PubMedPMID:34636401;PubMedCentralPMCID:PMCPMC8852215","volume":"107","author":"MK Javaid","year":"2022","unstructured":"Javaid MK, Ward L, Pinedo-Villanueva R, Rylands AJ, Williams A, Insogna K et al (2022) Musculoskeletal features in adults with X-linked hypophosphatemia: an analysis of clinical trial and survey data. J Clin Endocrinol Metab 107(3):e1249\u2013e1262. https:\/\/doi.org\/10.1210\/clinem\/dgab739.PubMedPMID:34636401;PubMedCentralPMCID:PMCPMC8852215","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1374_CR86","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1097\/00005792-198911000-00002","volume":"68","author":"IR Reid","year":"1989","unstructured":"Reid IR, Hardy DC, Murphy WA, Teitelbaum SL, Bergfeld MA, Whyte MP (1989) X-linked hypophosphatemia: a clinical, biochemical, and histopathologic assessment of morbidity in adults. Medicine (Baltimore) 68(6):336\u2013352 (PubMed PMID: 2811660)","journal-title":"Medicine (Baltimore)"},{"issue":"7","key":"1374_CR87","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1007\/s00198-022-06385-z","volume":"33","author":"M Scorcelletti","year":"2022","unstructured":"Scorcelletti M, Kara S, Zange J, Jordan J, Semler O, Sch\u00f6nau E et al (2022) Lower limb bone geometry in adult individuals with X-linked hypophosphatemia: an observational study. Osteoporos Int 33(7):1601\u201311. https:\/\/doi.org\/10.1007\/s00198-022-06385-z","journal-title":"Osteoporos Int"},{"issue":"3","key":"1374_CR88","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3928\/01477447-20240122-02","volume":"47","author":"TG Costales","year":"2024","unstructured":"Costales TG, Dalury DF (2024) Four-year outcomes of cementless versus cemented fixation of a newly introduced total knee arthroplasty design. Orthopedics 47(3):161\u20136. https:\/\/doi.org\/10.3928\/01477447-20240122-02","journal-title":"Orthopedics"},{"issue":"2","key":"1374_CR89","doi-asserted-by":"publisher","first-page":"230","DOI":"10.7326\/0003-4819-100-2-230","volume":"100","author":"M Davies","year":"1984","unstructured":"Davies M, Kane R, Valentine J (1984) Impaired hearing in X-linked hypophosphataemic (vitamin-D-resistant) osteomalacia. Ann Intern Med 100(2):230\u2013232. https:\/\/doi.org\/10.7326\/0003-4819-100-2-230. (PubMed PMID: 6691666)","journal-title":"Ann Intern Med"},{"issue":"1\u20132","key":"1374_CR90","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3109\/00016488509108581","volume":"100","author":"S O'Malley","year":"1985","unstructured":"O\u2019Malley S, Ramsden RT, Latif A, Kane R, Davies M (1985) Electrocochleographic changes in the hearing loss associated with X-linked hypophosphataemic osteomalacia. Acta Otolaryngol 100(1\u20132):13\u201318. https:\/\/doi.org\/10.3109\/00016488509108581. (PubMed PMID: 4040696)","journal-title":"Acta Otolaryngol"},{"issue":"2","key":"1374_CR91","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.amjoto.2015.10.002","volume":"37","author":"S Kaya","year":"2016","unstructured":"Kaya S, Tsuprun V, H\u0131zl\u0131 \u00d6, Schachern PA, Paparella MM, Cureoglu S (2016) Cochlear changes in serous labyrinthitis associated with silent otitis media: a human temporal bone study. Am J Otolaryngol 37(2):83\u20138. https:\/\/doi.org\/10.1016\/j.amjoto.2015.10.002","journal-title":"Am J Otolaryngol"},{"issue":"3","key":"1374_CR92","first-page":"461","volume":"68","author":"P Sass","year":"2003","unstructured":"Sass P, Hassan G (2003) Lower extremity abnormalities in children. Am Fam Physician 68(3):461\u2013468 (PubMed PMID: 12924829)","journal-title":"Am Fam Physician"},{"issue":"6","key":"1374_CR93","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.pcl.2022.07.001","volume":"69","author":"E den Bakker","year":"2022","unstructured":"den Bakker E, B\u00f6kenkamp A, Haffner D (2022) Assessment of kidney function in children. Pediatr Clin North Am. 69(6):1017\u201335. https:\/\/doi.org\/10.1016\/j.pcl.2022.07.001","journal-title":"Pediatr Clin North Am."},{"issue":"2","key":"1374_CR94","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1172\/jci107774","volume":"54","author":"CY Pak","year":"1974","unstructured":"Pak CY, Oata M, Lawrence EC, Snyder W (1974) The hypercalciurias Causes, parathyroid functions, and diagnostic criteria. J Clin Invest. 54(2):387\u2013400. https:\/\/doi.org\/10.1172\/jci107774","journal-title":"J Clin Invest."}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-025-01374-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00223-025-01374-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-025-01374-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T13:20:42Z","timestamp":1766755242000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00223-025-01374-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":94,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1374"],"URL":"https:\/\/doi.org\/10.1007\/s00223-025-01374-w","relation":{},"ISSN":["1432-0827"],"issn-type":[{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,28]]},"assertion":[{"value":"20 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dieter Haffner received speaker fees, consultation fees, and research grants from Kyowa Kirin. Ineke B\u00f6ckmann declares that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"66"}}